Menu

Recent Interviews

Nick Mather, CEO, SolGold PLC

Nick Mather
CEO | SolGold PLC
1 King Street, EC2V 8AU London (GB)

emichael@solgold.com.au

+44 20 3823 2125

SolGold CEO Nick Mather on building a major gold and copper mining company


Jared Scharf, CEO, Desert Gold Ventures Inc.

Jared Scharf
CEO | Desert Gold Ventures Inc.
4770 72nd St,, V4K 3N3 Delta (CAN)

jared.scharf@desertgold.ca

Desert Gold Ventures CEO Jared Scharf on West Africa and its potential


Stephan Dorfmeister, Finance Department, Deep Nature Project GmbH

Stephan Dorfmeister
Finance Department | Deep Nature Project GmbH
Untere Hauptstraße 168, 7122 Gols (AT)

office@deep-nature.at

+43 681 10139055

Like Aurora Cannabis and Canopy Growth, Deep Nature Project GmbH focuses on value chain


29. July 2020 | 07:29 CET

BioNTech, Eastman Kodak, EXMceuticals - investors have the chance to profit

  • Health

The importance of health has not been as clear for a long time as it was in 2020. Detached from the discussion about the specifics of COVID-19 on mortality compared to other viruses, the need for protection is great and helplessness without a medical response is harmful to the common good. For this reason, experts around the globe are working to find active ingredients and reduce dependence on China for care. Investors have the opportunity to profit from this development.

time to read: 2 minutes by Mario Hose


 

Vaccine for COVID-19 under test

BioNTech describes itself as a next generation immunotherapy company that is pioneering the development of therapies for cancer and other serious diseases. Its activities focus on combining a variety of modern therapeutic platforms and bioinformatics tools to rapidly advance the development of novel biopharmaceuticals. Based on its extensive expertise in the development of mRNA vaccines, BioNTech is also working with collaboration partners to develop various mRNA vaccine candidates for a number of infectious diseases.

Together with Pfizer, BioNTech is working on the development of a vaccine for COVID-19, and the company recently announced that a vaccine candidate can participate in a Phase 2/3 study. The selection of candidates for this study has already been made based on data from the Phase 1/2 study in Germany and the USA. Up to 30,000 people aged between 18 and 85 years will participate in the study in approximately 120 study centers worldwide. If successful, up to 100 million vaccine doses will be made available by the end of the year and over 1.3 billion doses by the end of 2021.

Expanding independence from China

The capital market-oriented US President Donald Trump has announced that Eastman Kodak will receive a state loan of USD 765 million under the Defense Production Act. The company was formerly active in the photographic equipment sector and is known under the Kodak brand name. However, Kodak was not prepared for the success of digital photography and quickly fell into disarray. Management now plans to use the U.S. government's money to produce important ingredients for medicines.

In connection with the Corona Pandemic, it became clear how dependent the world community is on Chinese producers. Restrictions in supply chains led to bottlenecks in the supply of equipment to the population. In addition to Kodak, 3M for the production of protective masks and General Motors for the production of respirators were already able to benefit from the 1950 law in connection with the Korean War.

CEO increases stake in company

EXMceuticals is a young life science company focused on the wellness and medical applications of cannabinoids and terpenes. The subsidiary EXM Portugal has licenses and permits for cannabis research for its existing laboratory and pilot refinery in Lisbon. The company has already completed research projects with Universidade Nova de Lisboa and Universidade Lusofona and has applied for P2020 research grants.

In addition to the scientific mission, EXMceuticals claims that it is planning and building a much larger and additional plant in Portugal, which will be operated as an EU GMP refinery. Once this industrial refinery is completed and licensed, it will be used by the company as a base for the distribution of cannabis ingredients in the EU and North America on a commercial basis. The company's activities focus on the production of high-quality cannabis and hemp ingredients for the pharmaceutical, therapeutic, nutraceutical and cosmetic industries. The company intends to sell the produced ingredients to international medical markets. As part of a financing, CEO Jonathan Summers converted previous loans to EXMceuticals into shares of the company and now holds more than 16% of the voting rights.


Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

29. September 2020 | 10:51 CET

BioNTech, Bayer, Valeo Pharma: Share price jump ahead of quarterly results

  • Health

Investors' expectations of developments can drive the share price. When it comes to solving a problem or creating needs, the interest of the capital market is particularly high. Things get exciting for investors when the business model offers the possibilities of scalability. Attractive investment opportunities can be created in the fields of health and medicine, which offer extraordinary return opportunities.

Read

08. June 2020 | 11:30 CET

Aurora, Bayer, XPhyto - scalable growth markets with potential

  • Health

Health is the most precious good in the life of a human being. The preservation and improvement of the quality of life is a large business area. Investors around the globe have the opportunity to participate in many different areas of research and development of products and therapies. The development of new markets and preparations usually requires a lot of risk capital before the fruits can be harvested. At the latest when a scalable solution has been found to improve people's lives, then the value of the company increases.

Read

14. May 2020 | 13:11 CET

BioNTech, EXMceuticals, Shop Apotheke Europe, Symrise - Shares gaining momentum

  • Health

The easing of measures to contain the Corona Pandemic will be further extended and, in parallel, companies and their employees will be able to increase personal communications again. However, the curfew phase was also used for strategic decisions and developments, as investors can see from announcements in recent weeks. The situation represents a crisis for many people, but it is also an opportunity for change and a new beginning. Market participants have learned in recent months that dependence on China leads to many bottlenecks and global diversification is therefore necessary. Anyone who wants to be part of it must have the right shares in their portfolio.

Read